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Treatment of oncologic disease has improved significantly in the last decades and in the
future a vast majority of cancer types will continue to increase worldwide. As a result, many
patients are confronted with primary liver cancers or metastatic liver disease. Surgery in
liver malignancies has steeply improved and curative resections are applicable in wider
settings, leading to a prolonged survival. Simultaneously, radiofrequency ablation (RFA)
and liver transplantation (LTx) have been applied more commonly in oncologic settings
with improving results. To minimize adverse events in treatments of liver malignancies,
locoregional minimal invasive treatments have made their appearance in this field, in which
radioembolization (RE) has shown promising results in recent years with few adverse
events and high response rates. We discuss several other applications of RE for onco-
logic patients, other than its use in the palliative setting, whether or not combined with
other treatments. This review is focused on the role of RE in acquiring patient eligibility
for radical treatments, like surgery, RFA, and LTx. Inducing significant tumor reduction can
downstage patients for resection or, through attaining stable disease, patients can stay
on the LTx waiting list. Hereby, RE could make a difference between curative of palliative
intent in oncologic patient management. Prior to surgery, the future remnant liver vol-
ume might be inadequate in some patients. In these patients, forming an adequate liver
reserve through RE leads to prolonged survival without risking post-operative liver failure
and minimizing tumor progression while inducing hypertrophy. In order to optimize results,
developments in procedures surrounding RE are equally important. Predicting the remain-
ing liver function after radical treatment and finding the right balance between maximum
tumor irradiation and minimizing the chance of inducing radiation-related complications are
still challenges.
Keywords: radioembolization, liver malignancies, downstaging, bridge to transplantation, transplantation, future
liver remnant, hepatobiliary scintigraphy, dosimetry
INTRODUCTION
According to recent estimations, an increase in the global cancer
burden is expected from 12.7 million new cases in 2008 to 22.2
million by 2030 (1). As these numbers grow, so does the num-
ber of patients with liver malignancies. As primary liver cancer,
hepatocellular carcinoma (HCC) is the fifth most common cancer
worldwide. In metastatic liver disease, the incidence of colorec-
tal carcinoma (CRC) is high. It is the third most common cancer
worldwide (2). At the time of diagnosis, 14.5% of the patients
present with synchronous metastatic liver disease, of which 76.8%
is limited to the liver. Another 12.8% develops metachronous
liver metastases within 5 years after initial diagnosis (3). Many
other tumor cell types, including neuroendocrine tumors (NET),
cholangiocarcinoma (CC), and others, frequently present as liver-
dominant disease (4). By the time that the disease has spread to
the liver it is often difficult to treat with low response rate and
a dismal survival. For example, in patients with CRC presenting
with synchronous liver metastases, without palliative chemother-
apy survival is only 5–7 months. With palliative chemotherapy
survival increases to 22 months (5–7). In patients with unifocal
HCC (<5 cm) a 5-year survival of 7% and a median survival of
18 months is seen without resection. After surgical resection this
increases to a 33% and 47 months, respectively (8).
These numbers indicate a clear need for improvement of cur-
rent treatment strategies for liver malignancies. In recent years,
trans-arterial yttrium-90 (90Y) radioembolization (RE) has gained
rapid interest in the management of liver malignancies. High
response rates and a favorable toxicity profile make this an elegant
therapy, even in patients with underlying cirrhotic liver disease.
Compared to trans-arterial chemo-embolization (TACE), which
is commonly used in patients with HCC, RE results in similar
response rates, a comparable overall survival (OS) and less adverse
events (9–12). Currently, many phase 2–3 clinical studies on RE are
recruiting patients for efficacy evaluation and toxicity screening
in patients with primary liver malignancies compared to current
treatments [YES-P (13), SARAH (14), and SIRVENIB (15)] or
combined with current treatments [SORAMIC (16) and STOP-
HCC (17)]. In secondary liver malignancies, RE is investigated
in phase 2–3 trials for efficacy evaluation and toxicity combined
with chemotherapeutic regimes. Simultaneously, determining the
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place of RE in the treatment algorithm as a first-line, second-
line, or salvage therapy [SIRFLOX (18), EPOCH (19), FOXFIRE,
and SIR-step (20)]. At this point, RE is mostly used as an end of
line treatment modality. However, RE can also be applied in a pre-
operative setting before hepatic surgery, before ablative treatments
such as radiofrequency ablation (RFA), or before a combination of
those. In this review, the possible merits of RE in the pre-surgical
setting will be discussed.
Surgical eligibility depends on many factors, currently render-
ing 10–30% of HCC patients and 5–9% of CRC patients eligible for
primary surgical resection (5, 6, 21–23). When deemed ineligible
for radical treatments, providing sufficient tumor reduction, called
downstaging, might allow for radical treatments. Once down-
staging has occurred, selected patients could be eligible for liver
transplantation (LTx). However, availability of liver donors is lim-
ited and minimizing the chance of tumor progression while on the
waiting list is needed, since disease progression and death occur in
10–23% of the patients while being listed (24, 25). Prevention of
disease progression during this waiting period is called a bridge to
transplantation, and will be discussed in our second section. Once
patients are eligible for resection (not for transplantation), a suffi-
cient post-operative liver reserve is needed to avoid post-operative
complications and death due to hepatic failure. Inducing hypertro-
phy of the future remnant liver (FRL) by portal vein embolization
(PVE) is an accepted method to minimize the chance of post-
operative hepatic failure. After PVE, it takes about 3–6 weeks to
induce adequate hypertrophy and around 17.5% of the patients
experience tumor progression during this time interval, making
them ineligible for resection (26). In unilobar RE, hypertrophy of
the non-treated lobe has been described. Maybe using RE instead
of PVE to achieve hypertrophy could help overcome this problem
of tumor progression.
Using RE in the pre-operative setting, when patients may still
be treated with curative intent, requires special attention to issues
of efficacy and toxicity. After a short introduction to RE treatment
itself, the role of RE in downstaging disease and as a bridge to LTx
will be discussed. The role of RE in optimizing the future liver
remnant will also be discussed, as well as issues of dosimetry and
treatment accuracy.
RADIOEMBOLIZATION
Radioembolization is a liver-directed treatment using radioactive
microspheres. It is based on the dual blood supply of the liver
(i.e., the portal vein and the hepatic artery). The contribution of
the portal vein and hepatic artery to the blood flow of the nor-
mal liver parenchyma is circa 70 and 30%, respectively (27). For
liver malignancies, the hepatic artery is the primarily blood sup-
ply (28). RE uses these perfusion differences between tumors and
non-tumorous tissue to its advantage. The administered micros-
pheres mainly lodge in the tumor arterioles, leading to a high
tumor absorbed dose and a limited absorbed dose to the healthy
liver parenchyma. This is even more the case for hypervascular
tumors such as HCC and NET. In RE treatment planning these
and several other factors play an important role.
Adequate patient selection is required first of all. Performance
score (ECOG 0–2), adequate liver function (Child Pugh score A
or B; bilirubin levels <2 mg/dl), liver-dominant, or liver-limited
disease and a life expectancy of>3 months are of particular impor-
tance (22, 29). When patients comply with these initial criteria,
angiography follows. Injection positions for RE are planned during
angiography, necessary precautions are taken to prevent extra-
hepatic deposition of microspheres, and the distribution of the
microspheres is simulated by injecting 99mTc-macroaggregated
albumin (99mTc-MAA). This is followed by planar scintigra-
phy and SPECT(/CT) imaging to detect possible extrahepatic
deposition in abdominal organs and the lungs.
Once extrahepatic depositions have been excluded, treatment
activity may be calculated. Different methods apply for the dif-
ferent microspheres commercially available. Resin microspheres
(SIR-Spheres®, SIRTeX Medical Limited, Lane Cove, NSW, Aus-
tralia) and glass microspheres (TheraSphere®, BTG International
Ltd., Canada) are both FDA approved. Both have different activity
Table 1 | Dose calculation methods.
Microspheres Dose calculation method
SIR-spheres user manual (30) Empirical Tumor load ≤25%=2 GBq whole-liver delivery
Tumor load 25–50%=2,5 GBq whole-liver delivery
Tumor load ≥50%=3 GBq whole-liver delivery
Body surface area (BSA) A(GBq) = (BSA− 0.2)+
[
tumor volume
tumor volume + liver volume
]
in which:
BSA=0.20247 x height(m)0.725×weight(kg)0.425
Segmentation A(GBq) = D(Gy)×([T/N×Masstumor]+Massliver)
49670×
(
1− lung shunt fraction(%)100
) in which:
T/N = Activitytumor/MasstumorActivityliver/Massliver based on MAA-SPECT/CT
TheraSpheres user manual (31) A(GBq) = D(Gy)×Massliver(kg)
50×
(
1− Lung shunt fraction(%)100
) with an upper limit of
lung shunt dose: lung shunt
fraction(%)×A(GBq)=0.61 GBq
A, desired activity of microspheres; D, nominal dose to the liver; T/N, tumor to non-tumor ratio.
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calculation methods defined by the manufacturer (Table 1). One
method is advocated for glass microspheres, while three methods
can be used for resin microspheres; the so-called empirical, body
surface area (BSA) and partition method (Table 1).
After RE treatment, 90Y-brehmsstralung SPECT or 90Y-PET
is conducted to evaluate the distribution of the microspheres,
excluding extrahepatic depositions. Post-treatment imaging can
also be used for dosimetry. RE is generally a safe therapy, with
relatively few side effects. Most patients will experience a lim-
ited degree of acute side effects (<30 days after RE) at a con-
stitutional (fatigue and fever), gastrointestinal (nausea, emesis,
abdominal pain, and ulcer), or hepatic level (biochemically). Some
might develop late radiation effects, like RE-induced liver disease
(REILD), which may occur in up to 5% of patients treated with
RE (29, 32, 33).
DOWNSTAGING
Undoubtedly, surgery with curative intent is the most effective
treatment strategy for a patient with liver malignancy. Literature
has shown improved survival in HCC and CRC (liver metas-
tases) after resection of all liver tumors (34, 35). Surgical eligibility
depends on many factors, currently rendering 10–30% of the HCC
patients and 5–9% of the CRC patients eligible for primary metas-
tasectomy (5, 6, 21–23). Several contra-indications for surgical
resection are in order: multiple bilobar tumors, inadvertent tumor
localizations (near proximity to large blood vessels), inability to
create sufficient resection margins (>10 mm), or an inadequate
residual liver volume (liver remnant) (36, 37). Due to improve-
ments in surgical techniques, the number of liver metastases in
CRC has become less important and does not influence prognosis
(36–38). Patients with ≥4 liver metastases in CRC show a signif-
icantly poorer survival after resection with a 5-year survival of
23% compared to patients with 1–3 liver metastasis with a 5-year-
survival of 44% (39). In HCC, there is a direct relation between the
amount of tumors and survival. In solitary HCC, a 5-year survival
of 56% is seen and in all patients with multiple HCC’s survival is
shorter than 3 years after resection (40–42).
As an alternative, RFA is a well-accepted treatment modality
with good response rates in primary and secondary liver malig-
nancies (43). Like surgical resection, near proximity to large vessels
(“heat sink” effect; incomplete ablation) poses a problem (44, 45).
Furthermore, the tumor must be reachable with the RFA-probe.
RFA is adequate for tumors smaller than 3 cm to obtain com-
plete necrosis, so tumor size should not exceed 3 cm (46). In a
meta-analysis for HCC, surgical resection as primary treatment
is superior to RFA with regard to recurrence rates, but surgical
resection has more complications (47). For CRC results for RFA
are similar to surgical resection (48).
In patients originally ineligible for resection/RFA, will down-
staging followed by radical treatment [resection, RFA, and ortho-
topic liver transplantation (OLT)] truly lead to survival prolon-
gation? A recent article by Ramanathan et al., described a 14-year
experience of multiple treatments for HCC’s (25). Their popu-
lation was analyzed retrospectively and divided in three groups.
The first two groups were treated with an intention to trans-
plantation down the road (goal: downstaging). The first group
underwent transplantation eventually (Group 1, n= 139) and
the second group did not receive transplantation, due to pro-
gressive disease (PD) (Group 2, n= 93). The third group had
contra-indications for transplantation (Group 3, n= 484). Used
treatments included TACE, trans-arterial chemoinfusion (TACI),
RFA, resection, sorafenib, RE, or a combination. RE was not fre-
quently used and rarely as downstaging modality in the first two
groups (Group 1: 0/139, Group 2: 6/93, and Group 3: 55/484). The
5-year survival in the third group was only 4.4%. The second group
showed a 5-year-survival of 35%, which was significantly worse
than the transplantation-group, with a 5-year survival of 72.5%
(25). This puts the need for downstaging in perspective. Once sig-
nificant tumor reduction has occurred, patients with HCC can be
treated with radical treatments leading to prolonged survival.
In patients with larger tumors (i.e.,>3 cm; ineligible for RFA)
or with tumors ineligible for resection, downstaging might be
achieved by chemotherapy or biologicals, such as tyro-kinase
inhibitors. These systemic agents, however, are commonly accom-
panied by (serious) adverse events. In order to gain a controlled
and local tumor reduction, downstaging with RE seems a logi-
cal sequel. In contrast to surgery and RFA, tumor size and tumor
localization pose less of a problem for RE. The role of RE for down-
staging has predominantly been described in patients with HCC.
No randomized controlled trials have been performed on down-
staging patients using RE. Nonetheless, approximately 50% (range
29–67%) of the patients with HCC will be downstaged success-
fully (Table 2) (11, 49–52). Successful downstaging led to either
resection, RFA, or OLT in three studies, in which approximately
1/3 of the downstaged patients were transplanted (10–23% of the
total population) and 2/3 underwent resection or RFA (19–42%
of the total population) (11, 49, 50). Two other studies focused
on downstaging followed by OLT. Ibrahim et al. described eight
patients with a caudate lobe HCC treated with RE. Four patients
were downstaged successfully (50%) and three of them received
OLT (37% of the total population) (51). Vouche et al. treated
102 patients ineligible for RFA or resection with RE, which led to
OLT in 33 patients (32%); however, downstaging success rate was
not described (53). The remaining study by Tohme et al. had a
different study design, in which they retrospectively reviewed 20
transplanted patients that received RE as sole treatment as a bridge-
to-transplant. Of these patients, 33% was downstaged according
to imaging (52).
Out of six studies on downstaging prior to radical treatment,
two studies described a median time to response, defined as par-
tial response (PR) according to the World Health Organization
(WHO) response criteria, of 3.1–4.2 months, significantly shorter
than TACE with a median time to response of 10.9 months (11,
49). In concordance with literature on RE in a palliative setting,
Table 2 shows a high PR rate and even complete response (CR)
rate for HCC treated with RE. According to WHO, CR and PR
was seen in 0–13 and 50–61%, respectively (11, 49, 51). By the
European Association for the Study of the Liver criteria (EASL),
CR and PR were even better 37–47 and 39–50%, respectively (11,
51). The most recent articles have implemented modified response
evaluation criteria in solid tumors (mRECIST), which looks at
tumor size as well as enhancing patterns. With mRECIST good
results were shown with a CR and PR of 37–47 and 19–39%,
respectively (52, 53). These numbers are also comparable to the
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Table 2 | Response assessment and downstaging in HCC patients.
Reference N mRECIST % WHO % EASL % Downstaging
success rate
Median time to
response/
downstaginga
Resection
or RFA
OLT
CR PR CR PR CR PR % Months (range) %b %b
Kulik et al. (49) 34 NA NA NA 50 NA NA 67 4 (1.9–16.3) 34 23
Lewandowski et al. (11) 43 NA NA 0 61 47 39 58 3.1 (1.8–8.7) 42 21
Ibrahim et al. (51) 8 NA NA 13 63 37 50 50 NA NA 37
Iñarrairaegui et al. (50) 21 NA NA NA NA NA NA 29 NA 19 10
Tohme et al. (52) 20 37 19 NA NA NA NA 33 NA NA 100c
Vouche et al. (53) 102 47 39 NA NA NA NA NA NA NA 32
N, number of patients, NA, data not available.
aIn both studies defined as WHO PR.
bPercentage of total population.
cAll patients received a liver transplantation (study design).
numbers shown in an earlier published meta-analysis by Vente
et al. (54).
In HCC, downstaging with RE seems feasible. Moreover, com-
parable response rates have been described for other liver malig-
nancies. In metastatic CRC reported response rates ranged from
18 to 46%, in metastatic NET around 63% and in metastatic breast
carcinoma they ranged from 26 to 91% (55–57). Like RE in HCC
patients, randomized controlled trials are needed to better define
the role of RE in downstaging patients with primary or secondary
liver malignancies.
As discussed above, high response rates can be observed after
RE in many different tumor types. RE as mono-therapy can induce
CR, for example in up to 47% of HCC (see Table 2). The ques-
tion is, how accurate are the current imaging modalities and
its response criteria after RE therapy? Data of explanted livers
show interesting results after RE in patients with HCC, who were
downstaged for transplantation with RE. A correlation between
radiologic response on follow-up imaging and the degree of necro-
sis found in the explanted specimen has been suggested (Table 3)
(52, 58). In the study of Riaz et al., CR by EASL and PR by
WHO correlated well with complete necrosis in their popula-
tion of 33 transplantations, 1 surgical resection, and 1 autopsy.
No enhancement of the lesions on imaging corresponded with
complete necrosis in these cases. When using response criteria
EASL had a 100% positive predictive value (PPV) and speci-
ficity, whereas WHO PR had a PVV and specificity of 78 and
71%, respectively (58). On the other hand, in an earlier study
by Kulik et al. no correlation was described with WHO crite-
ria. It was incorrect in five of the six explanted specimens and
correct in the seventh resection specimen. However, all incor-
rect interpreted lesions (5/7) showed contrast enhancement on
imaging (49). More recently, mRECIST has been introduced in
HCC instead of WHO and EASL. Tohme et al. showed that
four of the five patients (80%) with CR by mRECIST had com-
plete necrosis in their explanted livers (52). In contrast, the
more recent study by Vouche et al. found that only 7 of 14
patients (50%) with CR by mRECIST had complete necrosis at
pathology (53).
These discordant results highlight the limitations of current
response criteria and its inability to consistently predict the degree
of necrosis in treated liver malignancies. There is no primary role
for 18F-fluorodeoxyglucose positron emission tomography (FDG-
PET) in HCC, due to its low sensitivity of 50–55% in an overall
HCC population (59, 60). Well-differentiated HCC’s show no to
minimal FDG-uptake, while high to intense FDG-uptake can be
seen in poorly differentiated/aggressive HCC’s (59–61). With this
knowledge, individual prognostication seems possible (62). In the
case of HCC and RE, currently two studies investigated the value
of FDG-PET. Sabet et al. performed an FDG-PET before and
after whole-liver RE in 33 patients. OS was best in FDG-negative
HCC’s (13 months), followed by FDG-positive HCC’s that showed
a metabolic response (defined as a SUVmax decrease of at least 20%;
10 months). Patients with FDG-positive HCC’s without metabolic
response had the worst prognosis (OS 5 months) (63). Kucuk et al.
investigated pre-treatment FDG-PET as a prognostication method
in 19 patients. A longer progression free survival (PFS) was seen
in the group with evident FDG-positive HCC’s prior to RE, com-
pared to low FDG-positive or FDG-negative HCC’s prior to RE
(20, 12, and 5 months, respectively). The author stated that the
evident FDG-positive HCC’s responded better to RE (64).
18F-fluorodeoxyglucose positron emission tomography could
be of better value to predict response in mCRC or metastases from
other primary cancers than the conventional response criteria (65).
A correlation between CEA and FDG-PET/CT has been described
in a few studies (66–68). The metabolic response observed by PET-
CT is based on a reduction in tumor load, and therefore, a decline
in CEA. This does not always correlate with the response assessed
on anatomical imaging (66, 68). Zerizer evaluated 25 patients with
metastatic colon cancer to the liver with CECT and PET/CT. PFS at
2 years and decline in tumor markers were the primary end-points.
Response on PET/CT was highly correlated with tumor markers
(p< 0.0001) and prediction of PFS, while response on CT was not
significantly correlated (68).
More PET/CT studies with histopathological correlation or
correlation with patient outcome are needed. Hypothetically, if
non-invasive imaging and its response criteria could better predict
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Table 3 | Explanted data of HCC patients.
Reference Number of OLT Degree of necrosis % Comments on correlation imaging
(% total population) and histopathology
100% 50–99% 0–50%
Kulik et al. (49) 7 (24) 71 NA NA No correlation between imaging and
histopathology
Riaz et al. (58) 35 (100) based on 38 lesions 61 24 15 EASL CR and WHO PR correlated well with
complete necrosis
Ibrahim et al. (51) 3 (37) 33 66 0
Tohme et al. (52) 20 (100) 25 30 45 Four of five patients with 100% necrosis had
CR according to mRECIST
Vouche et al. (53) 33 (32) 52 48 0 Limitation of mRECIST; in CR 50% only
partial necrosis
NA, data not available.
the degree of necrosis, patients could be stratified in time frames,
giving clinicians better means to triage patients eligible for OLT.
BRIDGE TO TRANSPLANTATION
Initially, the long-term results of OLT for HCC were disappointing
with high recurrence rates and low survival. Early 30-day mor-
tality was 21.3% after transplantation with septicemia and graft
failure as leading causes and 5-year survival was 15.2% with a
median disease-free survival of 5.2 months (69). In 1996, a land-
mark study by Mazzaferro et al. defined selection criteria for HCC
patients, the so-called Milan criteria (70). With the Milan crite-
ria, a subgroup of HCC patients could be identified, consisting of
patients with a single nodule up to 5 cm or <3 nodules <3 cm
without extrahepatic manifestation and no vascular invasion, who
achieve similar results after OLT as patients who receive OLT in
end-stage-cirrhosis without HCC. Many have since adopted the
Milan criteria and confirmed its success with a 5-year-survival of
>70% (71, 72). In contrast, with increasing experience, multiple
authors addressed the Milan criteria as being too restrictive. Care-
ful selection of patients remains a matter of debate, the fact of
the matter being the limited availability of liver donors worldwide
(71–73).
Once eligible for OLT, patients are placed on a waiting list.
Availability ranges from days to months. The incidence of disease
progression while listed is 10–23% and death during evaluation is
around 11% (24, 25). Since liver donors are scarce, bridging the
period of listing is essential. This clinical setting is called “bridge to
transplantation.” Many of the aforementioned modalities may be
used in this particular setting. Regional control as a bridge to trans-
plant by using either RE, TACE, RFA, resection, chemotherapy, or
a combination of these modalities is usually safe, without affecting
post-transplant survival (16). Both RE and TACE show promising
results in gaining regional control. As a bridge to transplantation,
time and quality of life play an important role.
Lewandowski et al. compared RE (n= 43) with TACE (n= 43)
as a bridge to transplantation (11). In their study, the median time
to progression was defined as the interval between PD by WHO
response criteria and the time of treatment. The median time to
progression for TACE vs. RE was 19.6 vs. 48.6 months, respectively
(p= 0.008). According to the EASL criteria, the 1-year progression
rate was 40% for TACE vs. only 8% for RE (p= 0.01). Given its
durable response in HCC, RE might, therefore, be the preferred
choice as a bridge to transplantation. Moreover, the group treated
with TACE was hospitalized for 3 days on average and received a
median of two treatments per patient. In contrast, the RE group
was treated on an outpatient basis and received a median of one
treatment per patient (11). As quality of life plays an increas-
ingly important role in medical decision-making, these logistical
benefits definitively favor RE over TACE in this setting. In the
developing field of RE even single session outpatient procedures
have been described, in which all procedures take 1 day in total
(74). Additionally, after treatment with≤3 GBq 90Y-microspheres
no contact restrictions are necessary for patients and their families
(75). Altogether these results are very promising, but need to be
reproduced in larger patient populations including quality of life
investigations.
Transplantation may not be restricted to HCC alone. Other
primary liver malignancies have shown promising results as well,
like CCs and hepatic epitheloid hemangioendotheliomas (76).
When it comes to secondary malignancies that are limited to
the liver, well-differentiated NET have been investigated for OLT
too. Primary treatment of a NET includes resection of the primary
tumor. Dissemination usually occurs at a later stage and is often
limited to the liver only. In NET, 60–70% of patients present with
diffuse, multifocal liver metastases, ineligible for radical treatments
(77). When NET patients present with limited liver metastases,
surgical resection results in only 10–25% curative resections with
a 5-year recurrence rate of around 80% (78).
Orthotopic liver transplantation may provide the best curative
treatment option for patients with metastatic NET, similar as to
OLT in HCC. Both producing NET and non-producing NET are
eligible for OLT and selection criteria for NET include the Milan
criteria of 2007 (78), which are adopted by the European Neu-
roendocrine Tumor Society guideline of 2012 (77). Logically, the
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Milan Criteria for NET are different from the Milan criteria for
HCC. They include only histologic confirmed well-differentiated
tumors, liver tumor load <50%, age <50 years and stable disease
for at least 6 months prior to OLT. With a 5-year-survival up to 90%
(range 33–90%) OLT seems promising in NET patients matching
these criteria. However, tumor recurrence after transplantation
may eventually pose a problem with a 5-year disease-free survival
rate ranging from 20 to 77% (79).
Radioembolization as a bridge to transplantation in NET may
have some benefit. As mono-treatment, the largest study to date on
RE in NET patients (n= 148) reported a response rate of 63% and
a disease control rate (defined as CR+PR+ stable disease) of 86%,
combined with a median survival of 70 months (56). With such
efficacy, RE may provide effective bridging in NET patients. No
studies have been performed to investigate this hypothesis. Cur-
rently in other secondary liver malignancies, OLT has no place in
the treatment algorithm. Some have used OLT in CRC, but within
2 years essentially all patients developed disease recurrence (76).
FUTURE REMNANT LIVER
As surgical techniques evolve, more patients will be candidates for
extensive liver surgery. Resections of liver segments or complete
lobes are well tolerated. However, careful patient selection is crucial
to avoid liver failure due to limited hepatic reserve after resection.
According to current standards, the FRL should account for more
than 25% of the total liver volume (TLV). In patients with under-
lying chronic liver diseases (like cirrhosis) this should be more
than 40% of TLV (80). Both cut-off values are based on volumet-
ric measurements on radiologic imaging, computed tomography,
or magnetic resonance imaging (CT or MRI).
Once patients are screened for resection and FRL is deemed
inadequate, PVE of the tumor-bearing lobe is often considered
to gain hypertrophy of the FRL, the non-embolized lobe. After
PVE, adequate hypertrophy can be accomplished in 3–6 weeks,
and extensive resections can be permitted (80). In cirrhotic liv-
ers and patients formerly treated with chemotherapy (especially
platinum compounds), hypertrophy of the FRL after PVE may
be insufficient (81, 82). After PVE, hypertrophy of the FRL may
range from 8.5% up to 69% (82). Several clinics have noticed a
similar phenomenon of hypertrophy of the non-treated lobe after
RE (83–88). Table 4 summarizes findings of mainly retrospective
studies on the degree of hypertrophy (DoH) of the non-treated
lobe. DoH is defined as the FRL volume minus the FRL volume
before treatment, divided by the FRL volume before treatment.
A DoH of approximately 35% has been observed at 3–4 months
after RE (range 8.9–57%). Garlipp et al. compared RE (n= 35)
with PVE (n= 141). In their population, PVE resulted in signif-
icantly more hypertrophy of the non-treated lobe compared to
RE after 1 month (61.5 vs. 29%) (88). The main limitation of this
study was the follow-up interval of 1 month. This might have been
too short to observe sufficient hypertrophy.
We have learned from studies with living donor LTx that the
liver has a steady pace in regeneration. In a study by Klink et al.,
after donation of a right liver lobe, the remaining left lobe had a
mean volume of 36.1% of the TLV (baseline) (89). After 1 month,
FRL was 54.8% of the pre-transplantation TLV (53.6% DoH).
After 3 months, 80% of the pre-transplantation TLV was restored
(146% DoH) and after 12 months the post-transplantation vol-
ume was equal to or even more than 100% of the initial TLV (267%
DoH) (89). This shows the value of a longer interval between the
induction of hypertrophy and surgery.
Vouche et al. showed a similar dynamic pattern in RE (Table 4)
with a DoH of 7% at 1 month, 35% at 3 months, and 45% at
9 months (87). In comparison, Corrêa et al. showed that PVE
resulted in a 50% DoH occurring in the first 90 days (approxi-
mately 3 months) and 75% by 230 days (approximately 8 months)
in patients who were not eligible for resection after PVE. The study
by Corrêa et al. included patients who experienced PD during
the time interval between PVE and surgical resection. This corre-
sponded with 26% of the total population treated with PVE (90).
Resection should be performed shortly after PVE, since signif-
icant tumor progression may be seen in the PVE lobe and tumor
progression can affect the FRL. Comparable to the previously men-
tioned study by Corrêa et al. and other studies, a study by de
Baere et al. showed a high rate of patients with tumor progres-
sion after PVE, rendering them ineligible for resection (81, 90). De
Baere et al. treated 106 patients with PVE and showed a DoH of
the FRL of 69% obtained within 27–52 days (mean 31± 5 days).
Subsequently, successful hemi-hepatectomies were performed in
88%, but 12% were deemed inoperable due to tumor progres-
sion, extrahepatic spread, or liver metastasis in the hypertrophic
lobe (81). In a recent analysis by Vyas et al., 17.5% of the patients
experienced tumor progression and 4.8% had failure of hyper-
trophy prior to surgery in a pooled population of 1532 patients
undergoing PVE (26).
Although at a slower rate, RE can induce substantial hypertro-
phy in the non-treated lobe while treating the tumor at the same
time. This may lead to less tumor progression during the interval
between RE and surgery. Unfortunately, no prospective trials have
yet been performed to investigate this hypothesis.
Another way to prevent tumor progression is to simply per-
form surgery sooner, before the tumor has the chance to progress.
There are some studies suggest that FLR volume is a subopti-
mal predictor of post-operative liver failure. Ideally, we should
look at FRL function to predict the chance of success (91, 92).
This especially becomes relevant in patients with underlying liver
disease, in whom some parts of the liver might have a better func-
tion than other parts. There are different methods for assessing
liver function. First assessment of liver function is usually done by
measurements of liver enzymes (aminotransferase levels and alka-
line phosphatase) and products indicative of liver synthesis such
as albumin, bilirubin, and prothrombin time in blood. However,
liver enzymes are markers of liver injury and products of hepatic
synthesis function can be affected by different extrahepatic factors
such as nutrition, hemolysis, antibiotic use, and systemic illness.
The most well-known and applied dynamic quantitative liver
function tests are the indocyanine green clearance (ICG) and
galactose elimination capacity. ICG is a tricarbocyanine dye,
cleared from the plasma by hepatocytes and excreted into the bile.
The ICG clearance test is considered the most accurate test to
evaluate the hepatic functional reserve before surgery and to pre-
dict post-operative mortality (93). The carbohydrate galactose is
metabolized nearly exclusively in the liver. The elimination rate
of galactose from the blood depends on the phosphorylation of
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Table 4 | Hypertrophy after RE.
Reference Patients Follow-up Volume Degree of hypertrophy Degree of atrophy
period measurement contralateral lobe (%) treated lobe (%)
Jakobs et al. (83) 32 139 days CT/MRI 8.9 21.2
Gaba et al. (84) 20 3 months CT/MRI 40 52
Ahmadzadehfar et al. (85) 24 44–66 days MRI 57 6
Edeline et al. (86) 34 3 months CT 29 23
Vouche et al. (87) 83 1 month CT/MRI 7 2
3–6 months 35 21
>9 months 45 32
Garlipp et al. (88)a 35 46 days MRI 29 NA
141
†
33 days
†
61.5
†
NA, data not available.
aOnly prospective study.
† RE vs. PVE, PVE results are marked.
galactose by galactokinase. Both these dynamic tests, in which mul-
tiple blood samples need to be taken, have been shown to predict
post-operative complications and mortality (94, 95). However,
they are not able to tell the surgeon how much of the liver can
be resected safely or whether there are regional differences in liver
function.
In order to appreciate regional differences in liver function,
you have to make them visible. In the past years, two differ-
ent nuclear medicine imaging techniques for assessment of liver
function have been developed: 99mTc-galactosyl human serum
albumin (99mTc-GSA) and 99mTc-IDA. 99mTc-GSA scintigraphy
measures the binding of 99mTc-GSA to its receptor (the asialogly-
coprotein receptor), which is expressed on functional hepatocytes
only. Liver function measured by 99mTc-GSA scintigraphy corre-
lates well with conventional liver function parameters, including
the ICG clearance test (96, 97). 99mTc-GSA has been shown to be
of value for pre-operative risk assessment of partial hepatectomy
(97, 98). One major limitation is the availability of 99mTc-GSA, as
it is only available for clinical use in Japan.
Hepatobiliary scintigraphy using 99mTc-iminodiacetic acid
analogs (99mTc-IDA), has been used since the 1970s for the
scintigraphic evaluation various biliary diseases. After uptake by
organic anion transporter peptides expressed on the hepatocytes,
IDA analogs are excreted in the bile by ATP-dependent export
pumps, without undergoing biotransformation (99). Therefore,
IDA agents are ideal tracers for the biliary tract. More recent, HBS
with IDA analogs has been used to evaluate liver function. Liver
uptake of IDA analogs can be influenced by high plasma levels
of bilirubin (100). Of all IDA analogs, 99mTc-mebrofenin has the
strongest resistance to displacement by high bilirubin concentra-
tions and it also has the highest hepatic extraction fraction. For
these reasons, 99mTc-mebrofenin is the most favorable IDA analog.
Erdogan et al. have shown that the hepatic uptake rate of 99mTc-
mebrofenin correlates well with the ICG clearance rate and is an
efficient method for determining liver function (101). The same
group from Amsterdam later showed that pre-operative HBS is
more valuable in estimating the risk of post-operative liver failure
than CT volumetry in patients with underlying liver disease (102).
They provided a FRL function cut-off value for the prediction
of post-operative liver failure. Because HBS is a pure functional
test, this cut-of-value is the same for patients with or without
underlying liver disease. Therefore, it can be used in patients
with a pre-operative unknown quality of liver parenchyma (99)
(Figures 1A–D).
With the use of SPECT-CT and CECT, assessment of liver
function at a segmental level becomes possible. Combining the
functional data from the SPECT and the anatomical information
of the CECT will enable an even more accurate estimation of the
post-operative liver function in the future.
There have been few studies on the effect of PVE on liver func-
tion compared to liver volume. In a study of 24 patients by De
Graaf et al., FRL volume and function were assessed 3–4 weeks
after PVE. FRL function increased significantly more than FRL
volume (103). Using 99mTc-GSA, other studies also describe that
the increase in function is more pronounced than the increase in
volume (91, 92). These findings suggest that the time between PVE
and surgery may be shortened, thereby leaving less time for tumor
progression.
DISCUSSION
In the previous sections, we described RE as an interval treat-
ment modality for downstaging, bridge-to-transplant and future
remnant hypertrophy. Although level 1 evidence is lacking, prelim-
inary results show promising accuracy of RE for these particular
indications.
Downstaging is feasible in patients with HCC as shown by sev-
eral authors (11, 49–53), but it should not be limited to HCC alone,
since response rates of other liver malignancies by RE are similar
or even higher, including a long-lasting effect. As described in our
review, gaining surgical eligibility leads to survival prolongation.
If patients are treated with an intention to downstage and when
sufficient tumor reduction has occurred, selected cases might even
be eligible for OLT, which is the most promising curative treatment
for several primary and secondary liver malignancies at this time,
as discussed in our review. If patients are not eligible for OLT and
the future liver remnant is deemed insufficient, the later making
the patient ineligible for resection as well, inducing hypertrophy
is paramount. In achieving sufficient hypertrophy RE might be
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FIGURE 1 | (A–D) Axial HBS SPECT-CT image through the abdomen of a
patient with hemochromatosis and multifocal HCC. Notice the regional uptake
differences in cirrhotic and tumorous tissue (A). Corresponding MRI T2
weighted image (B). Same patient before (C) and after (D) RE of the left lobe
including segment 4. (C) It is from the same HBS SPECT/CT as image (A),
but shown in a different axial plane. The decrease of 99mTc-mebrofenin uptake
after treatment is best visible in segment 4. The area of high uptake is biliary
excretion in a dilated bile duct.
preferred over PVE, because RE has the advantage of the combi-
nation of hypertrophy induction and local disease control. Success
of a combination of simultaneously downstaging and inducing
hypertrophy has already been described in a case report by Gulec
et al. (104).
Use of RE for downstaging, bridge-to-transplant and attaining
an adequate FRL seems very promising; however, several related
procedures need refinement too. Current imaging modalities and
their response criteria are incapable of predicting the degree of
tumor necrosis in lesions treated by RE (49, 53). A better determi-
nation of the degree of necrosis could assist clinicians in person-
alizing treatment algorithms and might even define the timing of
applying treatment (alternations). In improving related imaging
for these indications, hepatobiliary scintigraphy is taking the lead.
By determining liver function instead of liver volume, eligibility
for surgical resection could be attained sooner by evaluating func-
tion gain in the FLR, since functional and volume gain do not go
hand in hand. Furthermore, hepatobiliary scintigraphy takes an
underlying liver disease into account, like cirrhosis, which is not
uncommon in patients with HCC.
At the same time, dosimetry is crucial to optimize RE in these
settings. Theoretically, the higher the tumor absorbed dose, the
more effective. This rationale was supported by (pre-)clinical
studies in different settings (105–108). However, although the sur-
rounding normal liver cells are affected less, high activity levels can
result in loss of healthy liver parenchyma. Thus, the goal is to find
the right balance between maximum tumor absorbed dose and
preservation of healthy tissue in each individual patient. As briefly
pointed out in our introduction on RE, multiple activity calcula-
tion methods are being used. When using resin microspheres three
activity calculation methods have been described (Table 1). The
empirical method that was solely based on tumor load has been
abandoned due to an unacceptable toxicity profile and the lack
of any patient-individualized factors (29, 109). The BSA-method
(semi-empirical) has been used safely in many clinical trials and is
recommended in patients with concurrent or previous chemother-
apy by the manufacturer (30). It is easy to use in daily practice
and has strong historical data (77). However, this method has
been criticized in literature in many aspects, mostly based on not
taking liver volume into consideration. As a result, under- (small
patient+ large liver) or overtreatment (large patient+ small liver)
can occur (109, 110). Additionally, the BSA-method does not take
the tumor-to-non-tumor ratio (T/N ratio) into account, which is
to the disadvantage of patients with hypervascular tumors who
could withstand higher administered activities. The third calcula-
tion method, the partition model, embeds many of these relevant
factors. It takes into account the T/N ratio, tumor volume, and
liver volume. All variables in this equation can be acquired from
the 99mTc-MAA-SPECT/CT prior to RE, so no additional pro-
cedures are needed (111). Only poorly delineated tumors pose
a problem for quantification. The complexity of the partition
method makes its use less attractive in daily practice. In daily
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practice, the BSA-method is most commonly applied method for
dose calculation (111). Nonetheless, the partition model based
on the 99mTc-MAA-SPECT/CT findings should be preferred by
clinicians (111).
In the case of glass microspheres, the manufacturer advo-
cates one activity calculation method (Table 1), in which the
T/N ratio has not been included (31). Like the discussion sur-
rounding activity calculation for resin microspheres, treatment
based on prior 99mTc-MAA-SPECT/CT has been shown feasi-
ble for glass microspheres and seems very promising (108). One
should bear in mind though that the result of the 99mTc-MAA-
SPECT/CT is influenced by many factors, causing discrepancies
between 99mTc-MAA-particles distribution and 90Y-microspheres
distribution on which dose calculation is based, when applying the
partition method (summarized in Table 5).
As mentioned in our short introduction to RE, 90Y-
brehmsstralung SPECT/CT or 90Y-PET/CT is acquired post-
treatment to evaluate the distribution of the microspheres. At the
same time,both modalities can be used for post-treatment dosime-
try. Currently, 90Y-PET/CT is favored over 90Y-brehmsstralung
SPECT/CT by many RE-centers (114–119). Calculating the
administered tumor absorbed dose on post-treatment imaging
gives insight into the expected response. Several studies showed
that the tumor absorbed dose was correlated to the objective
response (115, 117, 120, 121). Additionally, heterogeneity of the
absorbed dose within the tumor can be assessed, which correlates
with the partial/regional tumor response (115, 119, 120).
Table 5 | Factors causing 99mTc-macroaggregated albumin
(99mTc-MAA) and 90Y-Microspheres (90Y-MS) distribution discrepancy
(27, 110, 112, 113).
Procedural aspects
Catheter positioning Similar positioning in both angiographies
Equal proximity to bifurcations
Injection rate Bolus or rapid (MAA) vs. intermitted delivery
(90Y-MS)
Particle aspects
Particle flow dynamics Randomly formed 99mTc-MAA vs. spherical
90Y-MS
Administered amount 99mTc-MAA±150.000 particles vs. 90Y-MS ±4–50
million particles
Technical aspect
Patient positioning Registration mismatch between scans
Shortcomings imaging Variability in delineation of tumors
Threshold definition of tumor vs. non-tumor
Scanning modality 90Y-Brehmstralungs-SPECT/CT vs. 90Y-PET/CT
Breathing artifacts Registration difficulties between scans
Patient factors
Primary tumor Ability of tumor delineation on imaging
Vascular Artery spasms during delivery
Stasis of flow during 90Y-MS administration
In downstaging and bridge-to-transplant, dosimetry should
optimize the tumor absorbed dose, while delivering an acceptable
to minimal dose on healthy liver tissue. Applying the parti-
tion method based on the 99mTc-MAA-SPECT/CT is preferable
and when possible, super-selective catheterization of the tumor-
bearing lobe can be considered to further improve tumor dose
and healthy liver dose differences. By doing so, minimizing radi-
ation induced complications and preserving healthy liver tissue,
which is badly needed after surgical resection. However, the vast
majority of the current studies did not use dose calculations
based on the 99mTc-MAA-SPECT/CT, so optimal dose calcula-
tion might not have been reached and downstaging success rates
could be even higher (11, 49–53). Additionally, minimizing lung
shunting and preserving lung function before an intensive liver
transplant procedure or large surgical resection, may become an
additional aspect to consider. In LTx, peri-operative death occurs
in 5.3–7.0%, mostly due to multiple organ failure (including res-
piratory insufficiency) and approximately 42.1% of all patients
develop pulmonary complications (pneumonia and pleural effu-
sion) after LTx (122, 123). In current studies performing RE as a
bridge to transplantation, none specifically mentioned pulmonary
complications after OLT (11, 49–53).
In the induction of FRL hypertrophy, the underlying mech-
anism of liver hypertrophy remains a mystery (82). Since the
embolic effect of RE is less substantial than in PVE, remnant
hypertrophy after RE might largely be based on an irradiation
induced effect in the treated liver lobe. This causes fibrosis, lead-
ing to increased portal pressure and eventually to shunting of
portal venous blood away from the irradiated fibrotic lobe to the
untreated contralateral lobe by preferential flow (83, 84, 86). This
effect and its results do not arise as rapidly as in PVE, as described
by Vouche et al. and Corrêa et al. (87, 90). After PVE, a more
macroscopic occlusion creates a sudden shunt of portal venous
blood to the untreated lobe. In some cases, repeated RE resulting
in a higher cumulative dose led to an increase in hypertrophy of
the untreated lobe (50). Only Edeline et al. found no correlation
between the absorbed dose and hypertrophy in their study (86).
That study was soon followed by a multivariate analysis of Vouche
et al., in which the absorbed dose was no significant variable (87).
Nonetheless, no studies have been performed solely to investigate
this phenomenon and its relation to dose.
Apart from assessing FRL function with HBS, HIDA could be
a very interesting modality when it comes to RE. At present, there
have been no studies evaluating the effect of RE therapy on liver
function apart from laboratory toxicity. In the future, scintigraphy
can be used to learn us more about changes in liver function after
RE, for example in relationship to microsphere distribution and
dose. Another area of research could be time to functional recovery
after RE, which in turn could potentially be helpful in determining
when to perform repeat RE treatment if needed.
CONCLUSION
Trans-arterial treatment of liver malignancies with RE is an
emerging treatment modality. RE is predominantly performed
in patients with no curative options, mostly in a salvage setting.
Potentially curative settings in which RE may be applied include
downstaging patients to resec disease, a bridge to transplantation
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and induction of remnant liver hypertrophy. RE involves a com-
bination of tumor reduction and disease control, minimizing the
chance of tumor progression during the time interval prior to liver
surgery with curative intent. This may eventually lead to prolonged
survival, although prospective controlled trials are needed to test
this hypothesis. Imaging is indispensable for patient selection and
dosimetry-based treatment planning to use the full potential that
RE has to offer in patients with liver malignancy, especially when
liver surgery with curative intent might still be an option.
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